![IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway](https://www.mdpi.com/ijms/ijms-21-00957/article_deploy/html/images/ijms-21-00957-g003.png)
IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway
![The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ... The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ...](https://www.thelancet.com/cms/attachment/36095ed8-7b85-4a20-8bc4-3ac4fa70ecad/gr1_lrg.jpg)
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from ...
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval: 1959 These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval: 1959](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=cyclophosphamide-for-injection-usp-2.jpg&id=606181)
These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval: 1959
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959 These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-08.jpg&id=515396)
These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE for injection, for intravenous useInitial U.S. Approval: 1959
![These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE INJECTION safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE INJECTION. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval ... These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE INJECTION safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE INJECTION. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval ...](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=cyclophosphamide-fig2.jpg&id=584243)
These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE INJECTION safely and effectively. See full prescribing information for CYCLOPHOSPHAMIDE INJECTION. CYCLOPHOSPHAMIDE injection, for intravenous use Initial U.S. Approval ...
![Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies | Bone Marrow Transplantation Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies | Bone Marrow Transplantation](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41409-022-01908-y/MediaObjects/41409_2022_1908_Fig1_HTML.png)
Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies | Bone Marrow Transplantation
![Journal of Prescribing Practice - Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion Journal of Prescribing Practice - Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion](https://www.prescribingpractice.com/media/qi5p2ayx/jprp-2022-4-8-342_f01.jpg)
Journal of Prescribing Practice - Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion
![Frontiers | High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization Frontiers | High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization](https://www.frontiersin.org/files/Articles/548602/fphar-11-00775-HTML/image_m/fphar-11-00775-g001.jpg)
Frontiers | High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization
![Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ... Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...](https://www.astctjournal.org/cms/asset/9128c19c-393e-4e3e-90aa-ce3b3f824fc5/ga1.jpg)
Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...
![Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-020-0171-1/MediaObjects/41523_2020_171_Fig1_HTML.png)
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer
![Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ... Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...](https://www.astctjournal.org/cms/attachment/698908d4-81ac-4adb-b145-4a5070f2c653/ga1_lrg.jpg)
Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society ...
![Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study | Lupus Science & Medicine Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study | Lupus Science & Medicine](https://lupus.bmj.com/content/lupusscimed/9/1/e000779/F1.large.jpg)